Lonza Opens Drug Product Services Lab in Switzerland

Swiss multinational life sciences company Lonza held a ceremony in Basel, Switzerland Wednesday to celebrate the opening of its pharmaceutical Drug Product Services laboratories, where scientists will develop new formulations, engage in drug product analytical development and perform quality control activities.

The 1300 m2 facilities in Basel’s Stücki Science Park will be led by Hanns-Christian Mahler and will aid Lonza’s customers in developing drug product programs.

“We chose Basel for Lonza’s first-ever drug product development facility because it offers us access to the latest technologies and world-leading experts in a central location, one that’s a hub of innovation in the pharma industry,” said Richard Ridinger, chief executive officer of Lonza, in a statement.

Providing particle testing, container integrity closure testing, examinations for pharmaceutical product impurities, like leachables and extractables from plastics employed in manufacturing, and other services, the company’s Drug Product Services laboratories will offer standalone services or comprehensive drug product development programs. The Lonza facilities can help customers with formulation, stability, primary packaging, process development, and manufacturing.

“The addition of drug product development services to Lonza’s global offerings is the next part of our journey along the healthcare continuum, a step that moves us closer to our customers and their patients,” said Ridinger.

For more information, visit Lonza Drug Product Services.